| CAS NO: | 1132681-38-9 |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| Cas No. | 1132681-38-9 |
| 别名 | 5-氯-N-[[(5S)-2-氧代-3-[4-(3-氧代-4-吗啉基)苯基-2,3,5,6-D4]-5-恶唑烷基]甲基]-2-噻吩甲酰胺,BAY 59-7939-d4 |
| Canonical SMILES | O=C(C1=CC=C(Cl)S1)NC[C@H]2CN(C3=C([2H])C([2H])=C(N4C(COCC4)=O)C([2H])=C3[2H])C(O2)=O |
| 分子式 | C19H14D4ClN3O5S |
| 分子量 | 439.91 |
| 溶解度 | DMSO: Soluble |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Rivaroxaban D4 (BAY 59-7939 D4) is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM)[1][2]. [1]. Roehrig S, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem. 2005 Sep 22;48(19) [2]. Perzborn E, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005 Mar;3(3):514-21. |
m.cnreagent.com